NCT05890001已完成3 期
A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease
Braintree Laboratories60 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2023年4月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 400
- 试验地点
- 60
- 主要终点
- Frequency of treatment-emergent adverse events
研究概览
简要总结
The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have completed the BLI5100-301 or BLI5100-302 study with no serious AE (SAE) related to study drug and no major Protocol Deviations;
- •Able to understand and comply with the protocol requirements;
- •Willing and able to provide written informed consent at Screening;
- •Is a female of non-childbearing potential, or If a female of childbearing potential, agrees to use an acceptable form of birth control and avoid egg donation from the Screening Visit until 6 months after the last dose of study drug;
- •If a male, agrees to use an acceptable form of birth control from the Screening Visit until 3 months after the last dose of study drug;
- •If a male, agrees to abstain from sperm donation through 3 months after administration of the last dose of study drug;
- •Have documented healed EE (BLI5100-301 study patients only).
排除标准
- •History of alcoholism, or substance abuse/addiction in the year before enrollment in the BLI5100-301 and BLI5100-302 studies;
- •Note: Patients on prescribed opioids are eligible to participate if they have been on a stable dose for the duration of the BLI5100-301 and BLI5100-302 studies.
- •Note: Retesting of a positive urine drug screen requires Medical Monitor approval. Positive urine drug screen for all drugs will require verification of prescription for the positive tested substance.
- •A diagnosis of manic-depression, anxiety disorder, panic disorder, somatoform disorder, personality disorder, or other psychological disorder is exclusionary, unless the patient is asymptomatic and well-controlled. Stable treatment, including non-medical therapy, is preferred, but minor adjustments can be made and should be consulted with the Medical Monitor;
- •Current use of antipsychotics, antidepressants, anxiolytics, or prescription sleeping medications, with the exception of a stable dose for the duration of the BLI5100-301 and BLI5100-302 studies;
- •Requirement of persistent (>3 times per week for >30 days) use of non-steroidal anti-inflammatory drugs (NSAIDs) during the course of the study;
- •o Note: Low-dose (≤100 mg/day) aspirin is allowed provided that it has been used for prophylaxis prior to study participation.
- •If a female, is pregnant, breastfeeding, or planning to become pregnant during the study or within 6 months after the last dose of study drug;
- •Abnormal laboratory results with clinical relevance at Screening as follows:
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase level of ≥2 × upper limit of normal (ULN);
- •Total bilirubin level of ≥2 × ULN, unless Gilbert's syndrome is confirmed when direct bilirubin is ≤0.3 mg/dL;
- •Estimated glomerular filtration rate <30 mL/min.
- •Note: A lab value obtained during the Screening period may be retested once with Medical Monitor approval.
- •Abnormal ECG of clinical significance;
- •Involvement in another clinical study (other than BLI5100-301 and BLI5100-302 studies) within 4 weeks of initiation of study drug;
- •Any other clinically relevant condition that would confound study endpoints or adversely affect patient compliance with the study procedures in the medical judgment of the Investigator or Medical Monitor based on previous medical history or findings on Screening assessments.
研究组 & 干预措施
BLI5100 Low Dose
Experimental
Patients will take BLI5100 Low Dose once daily, orally, for up to 29 weeks.
干预措施: BLI5100 (Drug)
BLI5100 High Dose
Experimental
Patients will take BLI5100 High Dose once daily, orally, for up to 29 weeks.
干预措施: BLI5100 (Drug)
结局指标
主要结局
Frequency of treatment-emergent adverse events
时间窗: 31 Weeks
次要结局
未报告次要终点
研究者
研究点 (60)
Loading locations...
相似试验
已完成
1 期
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120NeoplasmsNCT00715403Boehringer Ingelheim41
已完成
3 期
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT01316887GlaxoSmithKline563
已完成
3 期
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With AsthmaAsthmaNCT01244984GlaxoSmithKline243
已完成
3 期
Long-Term Evaluation of BIIB067 (Tofersen)ALS Caused by Superoxide Dismutase 1 (SOD1) MutationNCT03070119Biogen139
终止
1 期
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisNCT04288856Biogen75